{"protocolSection":{"identificationModule":{"nctId":"NCT05880524","orgStudyIdInfo":{"id":"RESCIND-1-2023"},"secondaryIdInfos":[{"id":"2022-003410-37","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Ludwig-Maximilians - University of Munich","class":"OTHER"},"briefTitle":"Reduction of SystemiC Inflammation After Ischemic Stroke by Intravenous DNase Administration (ReSCInD)","officialTitle":"Reduction of SystemiC Inflammation After Ischemic Stroke by Intravenous DNase Administration (ReSCInD)","acronym":"ReSCInD"},"statusModule":{"statusVerifiedDate":"2023-12","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-12","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2024-12","type":"ESTIMATED"},"completionDateStruct":{"date":"2025-01","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-04-30","studyFirstSubmitQcDate":"2023-05-19","studyFirstPostDateStruct":{"date":"2023-05-30","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-12-11","lastUpdatePostDateStruct":{"date":"2023-12-12","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Martin Dichgans","investigatorTitle":"Sponsor-Delegated Person and Principal Investigator","investigatorAffiliation":"Ludwig-Maximilians - University of Munich"},"leadSponsor":{"name":"Ludwig-Maximilians - University of Munich","class":"OTHER"},"collaborators":[{"name":"University Hospital Erlangen","class":"OTHER"},{"name":"University Hospital Regensburg","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"The goal of this (monocentric, randomised, placebo-controlled single-blinded; phase 2) clinical trial is to test the hypothesis that DNase 1 administration leads to a reduction in systemic immune response measured in patients after acute ischaemic stroke compared to control treatment.\n\nParticipants will receive intravenous DNase 1 (500 µg/kg) or placebo (NaCl 0.9%) twice within 24±6 hours after symptom onset (last seen well). Blood samples will be taken at baseline, day 1 and 3. Personal visits will occur on baseline, day 1, 3 and discharge date. A telephone interview will be conducted on day 30±3."},"conditionsModule":{"conditions":["Ischemic Stroke","Inflammatory Response"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","interventionModelDescription":"Monocentric, randomised, placebo-controlled single-blinded, Phase 2 trial","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","whoMasked":["PARTICIPANT"]}},"enrollmentInfo":{"count":36,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Pulmozyme","type":"ACTIVE_COMPARATOR","description":"Dornase alfa; intravenous administration; 500 µg/kg","interventionNames":["Drug: Dornase Alfa"]},{"label":"Isotonic Saline Solution","type":"PLACEBO_COMPARATOR","description":"NaCl 0,9 %; intravenous administration; 0,5 ml/kg","interventionNames":["Drug: Isotonic Saline Solution"]}],"interventions":[{"type":"DRUG","name":"Dornase Alfa","description":"Patients will receive an intravenous dose of Dornase alfa twice within within 24±6 hours after symptom onset, administered as a bolus.","armGroupLabels":["Pulmozyme"],"otherNames":["Pulmozyme"]},{"type":"DRUG","name":"Isotonic Saline Solution","description":"Patients will receive an intravenous dose of Isotonic saline solution twice within within 24±6 hours after symptom onset, administered as a bolus.","armGroupLabels":["Isotonic Saline Solution"],"otherNames":["NaCl 0,9%"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Concentration of interleukin-1 beta in blood of patients with acute ischemic stroke receiving Dornase alfa compared to placebo treatment with Isotonic Saline Solution.","description":"Outcome of reduced systemic immune response measured by interleukin-1 beta concentration \\[pg/ml\\] (at 24±6 hours after symptom onset) measured by Enzyme-linked Immunosorbent Assay (ELISA).","timeFrame":"24±6 hours after symptom onset"}],"secondaryOutcomes":[{"measure":"cfDNA concentration in blood.","description":"Measurement of cell-free DNA (cfDNA) concentration \\[ng/ml\\] in blood at day 1 (24±6 hours after symptom onset) compared to the placebo group with experimental analysis.","timeFrame":"24±6 hours after symptom onset"},{"measure":"DNase 1 activity in blood.","description":"Comparison of DNase 1 activity \\[µU/ml\\] in blood of both treatment arms measured by Enzyme-linked Immunosorbent Assay (ELISA).","timeFrame":"24±6h after symptom onset"},{"measure":"Concentration of DNase 1 in blood.","description":"Analysis of the DNase 1 concentration \\[ng/ml\\] in patient blood treated with Dornase alfa compared to the placebo group by Enzyme-linked Immunosorbent Assay (ELISA).","timeFrame":"24±6h after symptom onset"},{"measure":"Analysis of the composition of the leukocyte population in blood.","description":"Analysing the leukocyte population \\[%\\] in blood using flow cytometry in both treatment arms.","timeFrame":"24±6 hours after symptom onset"},{"measure":"Interleukin-6 concentration in blood after treatment.","description":"Measurement of the interleukin-6 concentration \\[pg/ml\\] in blood samples (at 24±6 hours after symptom onset) measured by Enzyme-linked Immunosorbent Assay (ELISA).","timeFrame":"24±6 hours after symptom onset"},{"measure":"Caspase 1 concentration in blood after treatment.","description":"Analysing the caspase 1 concentration \\[pg/ml\\] in blood (at 24±6 hours after symptom onset) measured by Enzyme-linked Immunosorbent Assay (ELISA).","timeFrame":"24±6 hours after symptom onset"},{"measure":"Assessment of patient safety after Dornase alfa treatment.","description":"Safety aspects of intravenous investigational drug administration in acute ischemic stroke patients will be assessed by monitoring all study patients for 30±3 days and analysis of their:\n\n* routine clinical diagnostics (worsening stroke is defined as a) progression, hemorrhagic transformation of the index stroke documented by radiological imaging; b) life-threatening need for intervention; c) death from the index stroke; and/or d) increasing disability (as measured by an increase of ≥ 4 points from the lowest NIHSS score measured during hospitalization, or a 1-point increase in mRS),\n* laboratory parameters (hemoglobin, platelets, neutrophil granulocytes, leukocytes, CRP, GFR, creatinine, IL-6) and\n* number of adverse events assessed by CTCAE current version.","timeFrame":"30±3 days after symptom onset"},{"measure":"Comparison of the incidence of infections and antibiotic treatment in both treatment arms.","description":"Comparing the incidence of infections and antibiotic treatment after Dornase alfa and Isotonic Saline Solution treatment over a period of 30±3 days after symptom onset.","timeFrame":"30±3 days after symptom onset"},{"measure":"Functional neurological outcome scores (National Institute of Health Stroke Scale [NIHSS, 0-42] and Modified Rankin Scale [mRS, 0-6]) at both treatment arms.","description":"Analysing changes of neurological scores (National Institute of Health Stroke Scale \\[NIHSS, 0-42\\] and Modified Rankin Scale \\[mRS, 0-6\\]) from baseline to last visit 30±3 days after symptom onset.","timeFrame":"30±3 days after symptom onset"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with suspected acute ischemic stroke with symptom onset (last-seen-well) until Investigational drug application of less than 12 hours.\n* Consent to participate in the study.\n* Age ≥ 18 years.\n* NIHSS ≥10 at admission.\n\nExclusion Criteria:\n\n* Presence of any of the following conditions: Sinus or cerebral venous thrombosis, intracerebral haemorrhage, subarachnoid haemorrhage on qualified imaging (cCT with CT-A or MRI with MR-A). However, petechial haemorrhagic transformations of the index infarct and cerebral microhaemorrhages may be included.\n* Active malignant tumour disease in the last 6 months.\n* Current known immunosuppression due to immunomodulatory medication with immunosuppressive dose or underlying immunosuppressive disease (e.g. HIV).\n* Acute fulminant infectious disease in the last 7 days (fever \\> 38.5°C or suspected by the Investigator).\n* Breastfeeding or pregnant woman, women of childbearing age without known use of contraceptives with positive urine or serum beta-human choriogonadotropin test.\n* Ischemic stroke or myocardial infarction in the previous 30 days.\n* Surgery in the previous 30 days, except minor dermatological or gynaecological surgery without anaesthesia and wound healing disorders and patients with thrombectomy.\n* Estimated or known weight \\> 100 kg.\n* Known allergies or intolerance to dornase alfa (Pulmozyme) or recombinant protein products derived from Chinese hamster ovary cells.\n* Thrombocytopenia, leukocyte count \\<1500/μl.\n* Known participation in another clinical trial investigating a drug and/or medical product in the last 7 days before study inclusion.\n* Severe renal insufficiency with GFR≤29 ml/min/ 1.73m³ and/or renal insufficiency requiring dialysis.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Arthur Liesz, Prof. Dr.","role":"CONTACT","phone":"+49 89 4400 46242","email":"arthur.liesz@med.uni-muenchen.de"},{"name":"Saskia Wernsdorf","role":"CONTACT","phone":"+49 89 4400 46119","email":"saskia.wernsdorf@med.uni-muenchen.de"}],"overallOfficials":[{"name":"Martin Dichgans, Prof. Dr.","affiliation":"Institute for Stroke and Dementia Research, LMU Hospital","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Institute for Stroke and Dementia Research, Ludwig Maximilian University Munich, University Hospital","status":"RECRUITING","city":"Munich","state":"Bavaria","zip":"81377","country":"Germany","contacts":[{"name":"Arthur Liesz, Prof. Dr.","role":"CONTACT","phone":"+49 89 4400 46242","email":"arthur.liesz@med.uni-muenchen.de"},{"name":"Saskia Wernsdorf","role":"CONTACT","phone":"+49 89 4400 46119","email":"saskia.wernsdorf@med.uni-muenchen.de"},{"name":"Martin Dichgans, Prof. Dr.","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Arthur Liesz, Prof. Dr.","role":"SUB_INVESTIGATOR"}],"geoPoint":{"lat":48.13743,"lon":11.57549}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"},{"id":"D000007249","term":"Inflammation"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9983","name":"Inflammation","asFound":"Inflammation","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M21550","name":"Pharmaceutical Solutions","relevance":"LOW"}],"browseBranches":[{"abbrev":"PhSol","name":"Pharmaceutical Solutions"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}